clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Rickettsia Infections D012282 5 associated lipids
Splenic Diseases D013158 5 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Dyspepsia D004415 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Pyelonephritis D011704 5 associated lipids
Whooping Cough D014917 6 associated lipids
Bronchitis D001991 6 associated lipids
Skin Ulcer D012883 6 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Nocardia Infections D009617 6 associated lipids
Syphilis D013587 6 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Metaplasia D008679 7 associated lipids
Klebsiella Infections D007710 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Tooth Discoloration D014075 7 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Bacteriuria D001437 7 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Bronchiectasis D001987 7 associated lipids
Stomach Diseases D013272 7 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Chlamydia Infections D002690 7 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Leprosy D007918 8 associated lipids
Fistula D005402 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Renal Insufficiency D051437 8 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Lymphadenitis D008199 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Urethritis D014526 9 associated lipids
Sinusitis D012852 9 associated lipids
Bacteremia D016470 9 associated lipids
Urination Disorders D014555 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Romero-Gómez M et al. Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer. 2003 Aliment. Pharmacol. Ther. pmid:14616169
Perri F et al. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. 2001 Aliment. Pharmacol. Ther. pmid:11421878
Pilotto A et al. Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. 2001 Aliment. Pharmacol. Ther. pmid:11421879
Tepes B et al. Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? 2001 Aliment. Pharmacol. Ther. pmid:11421880
Miehlke S et al. Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance. 2003 Aliment. Pharmacol. Ther. pmid:14535873
Neri M et al. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. 2003 Aliment. Pharmacol. Ther. pmid:14535876
Pipkin GA et al. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. 1998 Aliment. Pharmacol. Ther. pmid:9768524
Labenz J et al. Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. 1997 Aliment. Pharmacol. Ther. pmid:9042979
Di Caro S et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. 2002 Aliment. Pharmacol. Ther. pmid:11876707
Gisbert JP and Calvet X Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. 2011 Aliment. Pharmacol. Ther. pmid:21745241
Savarino V et al. Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. 1999 Aliment. Pharmacol. Ther. pmid:9892878
Leiper K et al. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. 2008 Aliment. Pharmacol. Ther. pmid:18315579
Ford AC et al. Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. 2007 Aliment. Pharmacol. Ther. pmid:17944741
Zullo A et al. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. 2007 Aliment. Pharmacol. Ther. pmid:17539982
Lim AG et al. Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. 1997 Aliment. Pharmacol. Ther. pmid:9218079
Nista EC et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. 2004 Aliment. Pharmacol. Ther. pmid:15569121
Savarino V et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. 2000 Aliment. Pharmacol. Ther. pmid:10886045
Wang WH et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. 2000 Aliment. Pharmacol. Ther. pmid:10886046
Chen PY et al. Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. 2017 Aliment. Pharmacol. Ther. pmid:28074519
Zamani M et al. Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. 2017 Aliment. Pharmacol. Ther. pmid:28074507